Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer Inc. : U.S. Food and Drug Administration Extends Action Date for ELIQUIS® (apixaban) by Three Months

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2012 | 04:05am CEST

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis® (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The new Prescription Drug User Fee Act (PDUFA) goal date is June 28, 2012.

Subsequent to the filing of the NDA, the companies submitted additional information about the Eliquis clinical program to the FDA, which constitutes a major amendment to the application and will require additional time for review. The companies will continue to work closely with the agency to support the continued review of the NDA for Eliquis.

At this stage there are no plans for an FDA advisory committee meeting to review the NDA for Eliquis.

About Eliquis

Eliquis is the approved trade name for apixaban in Europe and the proposed trade name in the U.S. Eliquis is not approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation in any country. In May 2011, Bristol-Myers Squibb and Pfizer announced the first regulatory approval for Eliquis in the 27 countries of the European Union (EU) for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

Eliquis is being investigated within the EXPANSE Clinical Trials Program, which is projected to include nearly 60,000 patients worldwide across multiple indications and patient populations and includes a total of nine completed or ongoing, randomized, double-blind Phase 3 trials.

About the Bristol-Myers Squibb/Pfizer Collaboration

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer's global scale and expertise in this field.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Pfizer Inc.: Working together for a healthier world?

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

To learn more about our commitments, please visit us at www.pfizer.com.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that apixaban will receive regulatory approval for an indication in stroke prevention in patients with atrial fibrillation or that any such approval will be received within the time period described in this release. There is also no guarantee that, if approved in this indication, apixaban will become a commercially successful product. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2011, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

PFIZER DISCLOSURE NOTICE:

The information contained in this release is as of February 29, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about various potential indications for ELIQUIS (apixaban), including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical trial completion dates and regulatory submission and approval dates; decisions by regulatory authorities regarding whether and when to approve drug applications that have been or may be filed for any such indications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of any such indications; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

Bristol-Myers Squibb
Media:
Laura Hortas, 609-240-7025
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]
or
Pfizer Inc.
Media:
MacKay Jimeson, 212-733-2324
[email protected]
or
Investors:
Suzanne Harnett, 212-733-8009
[email protected]


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
04:49aPFIZER : Trademark Application for "RIXZURE" Filed
AQ
07/19PFIZER : An Application for the Trademark "COUNT ON BABY CHECKUPS, BECAUSE BABY ..
AQ
07/19PFIZER : Leaders from Pfizer, Sanofi, Eli Lilly and Applied Informatics to Speak..
AQ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK : Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and ..
AQ
07/19Pfizer's tanezumab meets in Phase III for OA pain
AQ
07/19PFIZER : Novartis joins Pfizer in deferring drug-price hikes
AQ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18PFIZER : Lilly pain drug meets late-stage trial goals
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 353 M
EBIT 2018 20 784 M
Net income 2018 13 077 M
Debt 2018 21 973 M
Yield 2018 3,63%
P/E ratio 2018 17,33
P/E ratio 2019 15,75
EV / Sales 2018 4,46x
EV / Sales 2019 4,25x
Capitalization 220 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,8 $
Spread / Average Target 5,7%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC220 236
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225